Status:
COMPLETED
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
Lead Sponsor:
AstraZeneca
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus...
Eligibility Criteria
Inclusion
- The subject has an HbA1c value \<=11.0%
- The subject has a body mass index (BMI) of 25 kg/m\^2 to 45 kg/m\^2, inclusive
Exclusion
- Is currently treated with certain medications, including exogenous insulin
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
456 Patients enrolled
Trial Details
Trial ID
NCT00111540
Start Date
November 1 2002
End Date
September 1 2006
Last Update
February 23 2015
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Anaheim, California, United States
3
Research Site
Bellflower, California, United States
4
Research Site
Burlingame, California, United States